The proteasome inhibitor MG132 induces nuclear translocation of erythroid transcription factor Nrf2 and cyclooxygenase-2 expression in human vascular endothelial cells.
Sahni
Sanjeev K
SK
Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA. Sanjeev_Sahni@urmc.rochester.edu
Rydkina
Elena
E
Sahni
Abha
A
D021581:Active Transport, Cell Nucleus / Q000187:drug effects; D002467:Cell Nucleus / Q000378:metabolism*; D002478:Cells, Cultured; D051546:Cyclooxygenase 2 / Q000235:genetics*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007976:Leupeptins / Q000494:pharmacology*; D051267:NF-E2-Related Factor 2 / Q000378:metabolism*; D061988:Proteasome Inhibitors; D012333:RNA, Messenger / Q000032:analysis
D015853:Cysteine Proteinase Inhibitors; D007976:Leupeptins; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; D061988:Proteasome Inhibitors; D012333:RNA, Messenger; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde